血液篩檢市場規模、佔有率、成長分析（按產品、技術、最終用戶、地區）- 2025 年至 2032 年產業預測

2023 年血液篩檢市場規模價值 25 億美元，預計將從 2024 年的 27.2 億美元成長到 2032 年的 53 億美元，預測期內（2025-2032 年）的複合年成長率為 8.7%。

全球對安全血液的需求和篩檢技術的進步正在塑造血液篩檢市場的未來。隨著全球捐血率的增加，需要進行全面的篩檢程序以確保捐血者的安全。這一趨勢在政府大力支持捐血舉措的國家尤其明顯，這些國家的良好基礎設施和公眾意識推動著捐血的增加。最近捐血的激增凸顯了對先進檢測方法來檢測感染疾病的需求，從而確保受血者的安全。大眾對愛滋病毒、B型肝炎、C肝和茲卡病毒等感染疾病的健康擔憂進一步凸顯了採用先進篩檢技術的重要性。因此，化學冷光免疫檢測(CLIA) 和核酸增幅檢查(NAT) 等技術正成為世界各地血液篩檢實驗室的標準。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 專利分析
• 監管分析
• 技術分析
• 案例研究

血液篩檢市場規模（按產品和複合年成長率） (2025-2032)

• 市場概覽
• 試劑和套件
  • 天然試劑與套件
  • ELISA 試劑和套件
  • 其他試劑和套件
• 裝置
  • 租賃購買
  • 完成購買
• 軟體和服務

血液篩檢市場規模（依技術及複合年成長率） (2025-2032)

• 市場概覽
• 核酸檢測（NAT）
  • 轉錄介導擴增（TMA）
  • 即時聚合酵素鏈鎖反應（RT-PCR）
• 血清學/免疫檢測
  • 化學冷光免疫檢測（CLIA）
  • 螢光免疫分析法（FIA）
  • 比色免疫檢測/ELISA（CI/ELISA）
• 快速檢測
• 西方墨點法
• 次世代定序（NGS）

血液篩檢市場規模（按最終用戶和複合年成長率） (2025-2032)

• 市場概覽
• 血庫
• 醫院

血液篩檢市場規模及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Abbott Laboratories（USA）
• Becton, Dickinson and Company（USA）
• Bio-Rad Laboratories, Inc.（USA）
• bioMerieux SA（France）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• Grifols, SA（Spain）
• Hologic, Inc.（USA）
• Quotient Limited（UK）
• Siemens Healthineers AG（Germany）
• Sysmex Corporation（Japan）
• Thermo Fisher Scientific Inc.（USA）
• Danaher Corporation（USA）
• Grifols Diagnostic Solutions Inc.（USA）
• Haemonetics Corporation（USA）
• Natera, Inc.（USA）
• Novartis International AG（Switzerland）
• Promega Corporation（USA）

結論和建議

Blood Screening Market size was valued at USD 2.5 billion in 2023 and is poised to grow from USD 2.72 billion in 2024 to USD 5.3 billion by 2032, growing at a CAGR of 8.7% during the forecast period (2025-2032).

The global demand for safe blood, coupled with advancements in screening technologies, is shaping the future of the blood screening market. As blood donation rates rise worldwide, the need for comprehensive screening procedures becomes essential to ensure donor safety. This trend is particularly prevalent in countries with robust government support for blood collection initiatives, where superior infrastructure and public awareness drive increased contributions. Recent surges in blood donations highlight the necessity for advanced testing methods to detect infections, thereby safeguarding recipients. Public health concerns over infectious diseases like HIV, hepatitis B and C, and Zika virus further emphasize the importance of adopting refined screening techniques. Consequently, technologies such as chemiluminescence immunoassays (CLIA) and nucleic acid amplification tests (NAT) are becoming standard in blood screening facilities globally.

Top-down and bottom-up approaches were used to estimate and validate the size of the Blood Screening market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Blood Screening Market Segments Analysis

Global Blood Screening Market is segmented by Product, Technology, End User and region. Based on Product, the market is segmented into Reagents & Kits, Instruments and Software & Services. Based on Technology, the market is segmented into Nucleic Acid Tests (NAT), Serology/Immunoassays, Rapid Tests, Western Blot Assays and Next-Generation Sequencing (NGS). Based on End User, the market is segmented into Blood Banks and Hospitals. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Blood Screening Market

The blood screening market is primarily driven by advancements in the understanding and response to infectious diseases, particularly the surge in bacterial and viral infections. There is a marked increase in the utilization of blood tests among healthcare professionals, fueled by evolving public health priorities aimed at monitoring disease outbreaks and guaranteeing the safety of blood transfusions. This trend reflects a heightened awareness of blood-borne infections and the critical need for early detection, prompting hospitals and clinics to invest in cutting-edge blood screening technologies. As a result, the market is poised for continued growth in the coming years, spurred by an emphasis on safety and preventive healthcare measures.

Restraints in the Blood Screening Market

A significant barrier to the blood screening market is the high cost associated with advanced screening tools and technologies. Many healthcare facilities, particularly in developing regions, find it challenging to afford the expensive blood screening equipment necessary for thorough testing. This financial constraint restricts their ability to implement comprehensive testing protocols, ultimately hindering market growth. The high costs not only limit the initial acquisition of the technology but also pose ongoing maintenance and operational expenses, further complicating the situation for healthcare providers and preventing them from keeping pace with advancements in blood screening practices.

Market Trends of the Blood Screening Market

The blood screening market is experiencing a significant shift towards point-of-care (POC) testing, driven by the need for rapid and decentralized diagnostics in healthcare settings. This trend enhances the delivery of near-instant results for essential laboratory tests, eliminating the delays associated with traditional sample processing at centralized labs. POC testing is increasingly being integrated into emergency rooms, outpatient clinics, and other medical facilities, facilitating quicker clinical decisions and improving patient experiences. As technological advancements continue to diversify POC blood screening options, the market is poised for robust growth, reflecting an increasing emphasis on efficiency and quality care in healthcare delivery.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Patent Analysis
• Regulatory Analysis
• Technology Analysis
• Case Studies

Global Blood Screening Market Size by Product & Service & CAGR (2025-2032)

• Market Overview
• Reagents & Kits
  • Nat Reagents & Kits
  • Elisa Reagents & Kits
  • Other Reagents & Kits
• Instruments
  • Rental Purchase
  • Outright Purchase
• Software & Services

Global Blood Screening Market Size by Technology & CAGR (2025-2032)

• Market Overview
• Nucleic Acid Tests (NAT)
  • Transcription-Mediated Amplification (TMA)
  • Real-Time Polymerase Chain Reaction (RT-PCR)
• Serology/Immunoassays
  • Chemiluminescent Immunoassays (CLIA)
  • Fluorescent Immunoassays (FIA)
  • Colorimetric Immunoassays/ELISA (CI/ELISA)
• Rapid Tests
• Western Blot Assays
• Next-Generation Sequencing (NGS)

Global Blood Screening Market Size by End User & CAGR (2025-2032)

• Market Overview
• Blood Banks
• Hospitals

Global Blood Screening Market Size & CAGR (2025-2032)

• North America (Product & Service, Technology, End User)
  • US
  • Canada
• Europe (Product & Service, Technology, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product & Service, Technology, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product & Service, Technology, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product & Service, Technology, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bioMerieux SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols, S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hologic, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quotient Limited (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols Diagnostic Solutions Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Haemonetics Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Natera, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Promega Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations